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Abstract
High mobility group box 1 (HMGB1), a highly conserved, ubiquitous protein, is released into the circulation during sterile
inflammation (e.g. arthritis, trauma)andcirculatory shock. Itparticipates in thepathogenesisofdelayed inflammatory responses
andorgandysfunction.WhileseveralmoleculeshavebeenidentifiedthatmodulatethereleaseofHMGB1, lessattentionhasbeen
paid to identify pharmacological inhibitors of the downstream inflammatory processes elicited by HMGB1 (C23-C45 disulfide
C106thiol form). In thecurrentstudy,acell-basedmedium-throughputscreeningofa5000+compoundfocused libraryofclinical
drugs and drug-like compoundswas performed inmurine RAW264.7macrophages, in order to identifymodulators of HMGB1-
inducedtumor-necrosis factoralpha (TNFa)production.ClinicallyuseddrugsthatsuppressedHMGB1-inducedTNFaproduction
included glucocorticoids, beta agonists, and the anti-HIV compound indinavir. A re-screen of the NIH clinical compound library
identified beta-agonists and various intracellular cAMP enhancers as compounds that potentiate the inhibitory effect of
glucocorticoids on HMGB1-induced TNFa production. The molecular pathways involved in this synergistic anti-inflammatory
effect are related, at least in part, to inhibition of TNFa mRNA synthesis via a synergistic suppression of ERK/IkB activation.
Inhibition of TNFa production by prednisolone+salbutamol pretreatment was also confirmed in vivo in mice subjected to
HMGB1 injection; this effect wasmore pronounced than the effect of either of the agents administered separately. The current
study unveils several drug-likemodulators of HMGB1-mediated inflammatory responses and offers pharmacological directions
for the therapeutic suppression of inflammatory responses in HMGB1-dependent diseases.
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Introduction
High-mobility group box 1 protein (HMGB1) was initially
considered a nuclear protein regulating gene transcription.
However, data emerging over the last decade identified its
separate role as a pro-inflammatory cytokine that is released
actively and passively from cells during inflammation and injury
[1–3]. According to a current classification, the immune response
can be regulated by endogenous danger signals (damage-associ-
ated molecular patterns; DAMPs; alarmins) as well as exogenous
pathogen-associated molecular patterns (PAMPs). In this context,
HMGB1 has been identified as a bona fide DAMP (i.e. a mediator
released during sterile inflammatory processes), as well as a
mediator released during PAMP-associated inflammatory events
(e.g. sepsis and septic shock), which participates in the pathogenesis
of the delayed inflammatory response, organ injury and contrib-
utes to disease mortality [1–3].
Significant work has focused on the molecular mechanisms of
HMGB1 release and on the therapeutic neutralization of
HMGB1, either by antibodies, or by inhibiting its binding to its
receptors RAGE and TLR4 [1–7]. Several compounds have been
identified that attenuate the release of HMGB1, including glucocor-
ticoids, chloroquine, gold salts, nicotinic receptor agonists, ethyl
pyruvate and inhibitors of poly(ADP-ribose) polymerase [3,8–11].
However, the inflammatory cellular responses downstream from
HMGB1 are less understood, and no systematic survey has been
conducted to characterize these pathways or to identify their
pharmacological modulators. One determinant of the bioactivity
of extracellular HMGB1 is based on the redox status of its three
conserved thiol groups. The all thiol confirmation has been show
to facilitate the binding of CXCL12 to CXCR4 and thus exhibit
chemokine-like properties [12]. The C23-C45 disulfide C106 thiol
conformation binds to the CD14/MD2/TLR4 receptor complex
[13,14] and demonstrates cytokine-like properties. Using a cell-
based medium-throughput screening approach, the goal of the
current study was to identify drug-like compounds that down-
regulate the cytokine-like activity of HMGB1-induced inflamma-
tory processes in murine macrophages in vitro.
Methods
Materials and Reagents
A comprehensive screening set of 5,546 compounds was
gathered comprising the NIH Clinical Collection (446 phase I–
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III trial compounds) from BioFocus (South San Francisco, CA),
the FDA Approved Library (640 FDA approved bioactive
compounds) from Enzo Life Sciences (Farmingdale, NY), the
Prestwick Chemical Library (1200 marketed drugs in Europe)
from Prestwick Chemical (Washington, DC), the US Drug
Collection (1040 clinical trial stage USP drugs), the International
Drug Collection (240 compounds marketed in Europe or Asia but
not in the US) and Killer Plates (160 toxic substances) from
MicroSource Discovery Systems (Gaylordsville, CT), the LO-
PAC1280 (1280 various biologically active compounds) from
Sigma-Aldrich, (Saint Louis, MO) and the Natural Products (640
natural compounds and derivatives) from TimTec LLC (Newark,
DE). The compounds were dissolved at 10 mM in dimethyl-
sulfoxide (DMSO) and dilutions were made either in DMSO or in
phosphate-buffered saline (PBS, pH 7.4) to obtain 0.5% final
DMSO concentration. HMGB1 (C23-C45 disulfide C106 thiol
form) was prepared as previously described [15] and diluted in
OptiMEM I medium (Invitrogen, Carlsbad, CA). Unless specified
otherwise, all other reagents were purchased from Sigma-Aldrich
Co. (St. Louis, MO).
Cell Culture
RAW 264.7 murine macrophages were obtained from the
American Type Culture Collection (ATCC, Manassas, VA) and
maintained in Dulbecco’s modified Eagle’s medium (DMEM)
(Hyclone, Logan, UT) containing 4.5 g/l glucose supplemented
with 10% fetal bovine serum (FBS, PAA Laboratories Inc,
Westborough, MA), 100 IU/ml penicillin and 100 mg/ml strep-
Figure 1. HMGB1 induces an inflammatory response in RAW 264.7 macrophages. A–B: RAW 264.7 cells were treated with the indicated
amount of HMGB1 and IFN-c for 18 hours and the TNFa secretion was measured in the supernatant. The viability of the cells was measured by the
MTT assay. (*p,0.05 compared to vehicle treated cells, #p,0.05 IFN-c treated group compared to the respective HMGB1-treated group) C: RAW
264.7 cells were treated with HMGB1 (5 mg/ml) for 1.5 hours and the expression of TLR-associated genes was analyzed with TLR signaling pathways
array. The gene symbols and the average fold-expression values are shown compared to vehicle-treated cells in the color-scale, according to the their
relative expression. (*p,0.05 compared to vehicle-treated cells.).
doi:10.1371/journal.pone.0065994.g001
Modulation of HMGB1-Mediated Inflammation
PLOS ONE | www.plosone.org 2 June 2013 | Volume 8 | Issue 6 | e65994
tomycin (Invitrogen, Carlsbad, CA) at 37uC in 5% CO2
atmosphere. Prior to HMGB1 stimulation the culture medium
was replaced with OptiMEM I reduced serum medium (Invitro-
gen, Carlsbad, CA).
Screening Assay
RAW 264.7 cells (100 000/well) were plated into 96-well tissue
culture plates and cultured overnight. Culture medium was
replaced with OptiMEM prior to adding compounds. Test
compounds were supplied at 10 mM in dimethyl sulfoxide
(DMSO) and were diluted in DMSO and in phosphate buffer
saline (PBS) to reach 3 mM final concentration (and 0.5% DMSO)
in the culture medium. The Natural Products Library was
screened at 1 mg/ml final concentration. Compounds were
administered in 1/20 volume 1 hour prior to HMGB1 treatment.
In the combined screen the cells received additional dexameth-
asone (3 mM) treatment. HMGB1 was added at 5 mg/ml final
concentration in 1/10 volume and the cells were incubated for 18
hours at 37uC in 5% CO2 atmosphere. Supernatant was collected
to measure TNFa secretion and LDH release.
Viability (MTT Assay) and LDH Release Measurements
The MTT assay and LDH activity measurements were
performed as previously described [16]. Briefly, the cells were
incubated in medium containing 0.5 mg?mL21,3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT, Calbio-
chem, EMD BioSciences, San Diego, CA) for 1 hour at 37uC at
5% CO2 atmosphere. The converted formazan dye was dissolved
Figure 2. Concentration- and time-dependence of the HMGB1-induced inflammatory response and reduction in cell viability in
RAW 264.7 macrophages. RAW 264.7 cells were treated with the indicated amount of HMGB1 for 24, 48 or 72 hours. A: Cell viability was
measured with the MTT assay and B: TNFa secretion was measured in the supernatant.
doi:10.1371/journal.pone.0065994.g002
Figure 3. Time-dependence of the HMGB1-induced suppression of cellular bioenergetics in RAW 264.7 macrophages. RAW 264.7 cells
were exposed to HMGB1 (5 mg/ml) for 24, 48 or 72 hours. Cellular bioenergetic parameters were measured with Seahorse extracellular fluid analysis.
A: Time-dependent decrease in basal cellular respiration (Oxygen Consumption Rate, OCR). (**p,0.01 compared to vehicle treated cells) B: Time-
dependent decrease in maximal cellular respiration. (*p,0.05 and **p,0.01 compared to vehicle treated cells). C: Representative tracing comparing
cellular respiration (Oxygen Consumption Rate) in response to sequential administration of pharmacological modulators of cell metabolism in
vehicle-treated cells or cells treated with HMGB1 for 72 hours. Basal Respiration, Calculated ATP Turnover, Proton Leak and Maximal Respiration areas
are indicated and demonstrate a marked suppression of cellular bioenergetic parameters.
doi:10.1371/journal.pone.0065994.g003
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in isopropanol and the absorbance was measured at 570 nm.
Serial dilution of the cells was used to calculate the count of viable
cells. Viability values are shown as percent values relative to
vehicle treated controls. LDH release was measured by mixing cell
culture supernatant (30 ml) with 100 ml LDH assay reagent
containing 110 mM lactic acid, 1350 mM nicotinamide adenine
dinucleotide (NAD+), 290 mM N-methylphenazonium methyl
sulfate (PMS), 685 mM 2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-phe-
nyl-2H-tetrazolium chloride (INT) and 200 mM Tris (pH 8.2).
The changes in absorbance were read kinetically at 492 nm for
15 min (kinetic LDH assay). LDH activity values are shown as
Vmax (mOD/min).
TNFa ELISA
Supernatant was diluted 10 times in PBS containing 1% bovine
serum albumin (BSA) and the TNFa levels were determined with a
commercially available ELISA kit (R&D Systems, Minneapolis,
MN) on a robotic system comprising of a plate washer (EL406,
Biotek, Winooski, VT), a dispenser (MicroFlo, Biotek, Winooski,
VT), a pipetting station (Precision, Biotek, Winooski, VT), an
incubator (Cytomat 2C, Thermo Electron Corporation, Asheville,
NC) and plate reader (Synergy 2, Biotek, Winooski, VT)
connected with a robotic arm (Twister II, Caliper Life Sciences
Inc, Hopkinton, MA).
RNA Isolation, Gene Expression Measurements
Total RNA was isolated from RAW 264.7 cells exposed to
HMGB1 or vehicle for 1.5 or 6 hours using a commercial RNA
purification kit (SV total RNA isolation kit, Promega, Madison,
WI). 2 mg RNA was reverse transcribed using the High Capacity
cDNA Archive kit (Applied Biosystems, Foster City, CA) as
previously described [17]. 1 mg RNA was used according to the
manufacturer’s protocol for gene expression measurements using
the Toll-like receptor signaling pathway real-time PCR array
(PAMM-0018ZD, SA Biosciences, Frederick, MD) on CFX96
thermocycler (Biorad, Hercules, CA) and analyzed with the tool
provided by SA Biosciences. A full list of the genes investigated is
deposited in Table S1. Taqman assay for TNFa was performed
using a commercial assay (TNFa assay ID: Mm00443260_g1, Life
Technologies, Carlsbad, CA) using GAPDH (VIC/MGB Probe,
Applied Biosystems, Foster City, CA) control as normalizer.
Western Blotting
Cells were lysed in denaturing loading buffer (20 mM Tris, 2%
SDS, 10% glycerol, 6 M urea, 100 mg/ml bromophenol blue,
200 mM ß-mercaptoethanol) freshly supplemented with 2 mM
sodium vanadate, 100 mM sodium fluoride, 20 mM beta-
glycerophosphate and protease inhibitors (Complete Mini
EDTA-free, Roche Applied Science, Indianapolis, IN). Lysates
were sonicated, boiled and resolved on 4–12% NuPage Bis-Tris
acrylamide gels (Invitrogen, Carlsbad, CA), then transferred to
nitrocellulose. Membranes were blocked in 10% non-fat dried
milk and probed overnight with phospho-ERK1/2, (Cell Signal-
ing, Boston, MA), phospho-p38 or phospho-IkB antibodies (Santa
Cruz Biotechnology Inc, Santa Cruz, CA). After incubation with
peroxidase conjugates the blots were detected on a CCD-camera
based detection system (GBox, Syngene USA, Frederick, MD)
with enhanced chemiluminescent substrate. To normalize signals,
membranes were stripped in 62.5 mM Tris, 2% SDS, 100 mM ß-
mercaptoethanol at 60uC for 30 min, blocked and re-probed with
antibodies against ERK1/2, p38 and IkB. The signals were
Figure 4. HMGB1 induces time-dependent caspase activation in RAW 264.7 macrophages. RAW 264.7 cells were exposed to HMGB1
(5 mg/ml) for 24, 48 or 72 hours. Activated Caspase-3 was detected in cell extracts by Western blotting. Tubulin was used for loading control. The
graph shows relative Caspase-3 activation values, normalized to tubulin. (**p,0.01 shows significant caspase activation compared to vehicle-treated
cells).
doi:10.1371/journal.pone.0065994.g004
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Table 1. List of hit compounds identified in the primary screen.






piperlongumine Natural Products anti-inflammatory, antioxidant 0 94
indapamide ENZO FDA sulphonamide diuretic 0 92
parthenolide Prestwick MAP kinase inhibitor anti-inflammatory 2 92
stattic LOPAC STAT3 activation inhibitor 14 125
parthenolide LOPAC MAP kinase inhibitor anti-inflammatory 20 104
U0126 LOPAC inhibitor of MEK1 and MEK2 (MAP kinase kinase) 20 92
rubescensin A Microsource Killer antibacterial, antineoplastic 21 93
29,49-dihydroxyflavone Natural Products flavone 21 83
ethylnorepinephrin Microsource US Drug adrenergic agonist, bronchodilator 22 112
parthenolide Natural Products MAP kinase inhibitor anti-inflammatory 23 102
dexamethasone Prestwick glucocorticoid steroid 23 100
betamethasone Prestwick glucocorticoid steroid 24 90
metaproterenol Prestwick beta-adrenergic agonist, bronchodilator 26 87
budesonide Prestwick glucocorticoid steroid 27 96
dexamethasone Microsource US Drug glucocorticoid steroid 29 107
hydrocortisone base Prestwick glucocorticoid steroid 29 115
tolnaftate Prestwick antifungal 29 90
fludrocortisone Prestwick mineralocorticoid, glucocorticoid 30 98
dexamethasone Microsource US Drug glucocorticoid steroid 30 106
fenoterol hydrobromide Prestwick beta-adrenergic agonist, bronchodilatator 31 100
tyloxapol Microsource US Drug polymeric nonionic detergent 31 92
triamcinolone Prestwick glucocorticoid steroid 31 92
6-alpha-methylprednisolone Prestwick glucocorticoid steroid 31 110
flumethasone Microsource US Drug glucocorticoid steroid 31 109
ST057244 Natural Products 32 85
isoalantolactone Natural Products sesquiterpene lactone 32 101
ritodrine Prestwick beta2 adrenergic agonist, tocolytic 32 98
imipenem Prestwick antibiotic 32 101
clenbuterol Prestwick beta-adrenergic agonist, bronchodilatator 32 98
prenylamine Prestwick Ca++ channel blocker, vasodilator 33 87
hydrocortisone Natural Products glucocorticoid steroid 33 113
lidocaine Prestwick Na+ channel blocker, local anesthetic 33 91
prednisolone Prestwick glucocorticoid steroid 33 107
flurandrenolide Microsource US Drug glucocorticoid steroid 33 116
prednisolone Microsource US Drug glucocorticoid steroid 34 110
bethamethasone Microsource US Drug glucocorticoid steroid 34 129
fluticasone Prestwick glucocorticoid steroid 34 78
clenbuterol Microsource Intl Drug beta2-adrenergic agonist, bronchodilatator 35 111
ibudilast LOPAC phosphodiesterase IV inhibitor 35 101
Bay 11-7085 LOPAC IkB phosphorylation inhibitor, inhibitor of NF-kB 35 94
fluocinolone Microsource US Drug glucocorticoid steroid 35 115
tulobuterol Microsource Intl Drug beta-adrenergic agonist, bronchodilatator 35 111
clobetasol propionate Prestwick glucocorticoid steroid 36 146
flurandrenolide Prestwick glucocorticoid steroid 36 107
prednisolone Natural Products glucocorticoid steroid 36 106
flunisolide Microsource US Drug glucocorticoid steroid 36 109
dexamethasone Natural Products glucocorticoid steroid 37 104
flumethasone Prestwick glucocorticoid steroid 37 133
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Table 1. Cont.






albuterol Microsource US Drug beta-adrenergic agonist, bronchodilatator 37 100
hydrocortisone Natural Products glucocorticoid steroid 37 109
flumethasone Microsource US Drug glucocorticoid steroid 38 117
nordihydroguaiaretic acid Natural Products from creosote bush, Larrea divaricata 38 92
2,6-dimethoxyquinone Microsource Killer antibacterial, mutagen 38 82
dichlorisone Microsource Int Drug glucocorticoid steroid 38 107
salbutamol Prestwick beta-adrenergic agonist, bronchodilatator 38 102
bethamethasone Microsource US Drug glucocorticoid steroid 39 114
hydrocortisone LOPAC glucocorticoid steroid 39 110
triamcinolone ENZO FDA glucocorticoid steroid 39 109
desoxymetasone Microsource US Drug glucocorticoid steroid 39 126
mometasone Prestwick glucocorticoid steroid 39 124
Bay 11-7082 LOPAC IkB phosphorylation inhibitor, inhibitor of NF-kB 39 95
prednisolone Microsource US Drug glucocorticoid steroid 39 110
fluorometholone Prestwick glucocorticoid steroid 39 104
3,7,49-trihydroxyflavone Natural Products flavone 39 81
budesonide Microsource US Drug glucocorticoid steroid 39 110
halomethasone NIH Clinical Collection glucocorticoid steroid 39 106
fluorometholone Microsource US Drug glucocorticoid steroid 40 114
triamcinolone Microsource US Drug glucocorticoid steroid 40 115
ST009819 Natural Products levoglucosenone derivative 40 101
prednisolone ENZO FDA glucocorticoid steroid 40 124
hydrocortisone Microsource US Drug glucocorticoid steroid 40 115
fluticasone NIH Clinical Collection glucocorticoid steroid 40 93
rimexolone Prestwick glucocorticoid steroid 40 96
isoproterenol Prestwick adrenergic agonist, bronchodilatator 40 109
methylprednisolone Microsource US Drug glucocorticoid steroid 41 115
methylprednisolone ENZO FDA glucocorticoid steroid 41 95
metaproterenol Microsource US Drug adrenergic agonist, bronchodilatator 41 104
karanjin Natural Products from Pongamia glabra, Leguminosae 41 100
salmeterol ENZO FDA beta2-adrenergic agonist, bronchodilator 41 111
betamethasone ENZO FDA glucocorticoid steroid 41 101
clobetasol Microsource US Drug glucocorticoid steroid 41 107
budesonide LOPAC glucocorticoid steroid 41 115
isotretinon Microsource US Drug antiacne, antineoplastic 41 115
benzyl isothiocyanate Microsource Killer antineoplastic, antibacterial, antifungal 41 89
quinacrine Microsource Killer anthelmintic, antimalarial, intercalating agent 42 77
flunisolide Prestwick glucocorticoid steroid 42 113
ellipticine LOPAC cytochrome P450 (CYP1A1) and DNA topoisomerase II
inhibitor
42 95
terbutaline hemisulfate Prestwick beta2-adrenergic agonist, bronchodilator 42 96
alclometazone Microsource US Drug glucocorticoid steroid 42 112
methylprednisolone Microsource US Drug glucocorticoid steroid 42 113
29,39-dihydroxyflavone Natural Products flavone 42 88
(+)-dehydroabietylamine Natural Products ingredient of rosin amine, from Rosin Gum 42 90
triamcinolone Microsource US Drug glucocorticoid steroid 43 113
betamethasone Microsource US Drug glucocorticoid steroid 43 112
isoflupredone Prestwick glucocorticoid steroid 43 99
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quantitated using Genetools analysis software (Syngene USA,
Frederick, MD).
Pharmacological Modulation of HMGB1-induced TNFa
Production in vivo
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of the University of Texas Medical Branch,
Galveston (Permit Number: 1110054). The procedures were
performed humanely with minimal suffering. 6–7 week-old
Balb/c male mice (The Jackson Laboratory) were pretreated
subcutaneously with 20 mg/kg prednisolone, 10 mg/kg salbuta-
mol, the combination of prednisolone and salbutamol (doses as
above), or the glucocorticoid receptor blocker mifepristone
(30 mg/kg) or the b-receptor antagonist propranolol (10 mg/kg)
or vehicle for 3 hours. Mice were injected intraperitoneally (i.p.)
with 0.5 mg/mouse HMGB1 and animals were sacrificed 8 hours
later. Serum levels of TNFa were measured by ELISA (as above).
Statistical analysis. Data are shown as means 6 SEM.
One-way ANOVA was applied for statistical analysis and for the
determination of significance, the Tukey’s post-hoc test was used.
A p value of ,0.05 was considered statistically significant. All
statistical calculations were performed using Graphpad Prism 4
analysis software. Experiments were performed at least 3 times on
different days.
Results
HMGB1 Induces Inflammatory Mediator Production and
Cytotoxicity in RAW 264.7 Macrophages
HMGB1 (1–10 mg/ml) induced concentration-dependent tu-
mor necrosis factor a (TNFa) secretion by RAW 264.7 cells, an
effect, which was potentiated by IFN-c (Fig. 1A). HMGB1 also
reduced cell viability (Fig. 1B); this cytotoxic response became
Table 1. Cont.






alclometasone Prestwick glucocorticoid steroid 43 147
p-aminobenzoate Microsource US Drug vitamin Bx 43 118
dexamethasone ENZO FDA glucocorticoid steroid 43 113
indinavir NIH Clinical Collection HIV protease inhibitor 43 96
ethacrynic acid Microsource US Drug diuretic 43 96
beclomethasone Microsource US Drug glucocorticoid steroid 43 112
amcinonide Microsource US Drug glucocorticoid steroid 43 109
MNS LOPAC Src and Syk kinase inhibitor 43 93
sulfasalazine Prestwick prostaglandin 15-hydroxydehydrogenase inhibitor 44 97
betamethasone Microsource US Drug glucocorticoid steroid 44 119
fludrocortisone Microsource US Drug mineralocorticoid, glucocorticoid 44 115
5,39-dihydroxyflavone Natural Products flavone derivative 44 99
methyl cholate Natural Products 44 97
desonide Microsource US Drug glucocorticoid steroid 44 115
tolazoline Prestwick alpha adrenergic antagonist, vasodilator 44 87
vincristine ENZO FDA antineoplastic, microtubular polymerization inhibitor 44 94
ethacrynic acid Prestwick diuretic 45 98
levonordefrin Prestwick adrenergic agonist, vasoconstrictor 45 116
isofluprednone Microsource US Drug glucocorticoid steroid 45 123
49-hydroxy-6-methoxyflavone Natural Products flavone 45 80
fluocinolone ENZO FDA glucocorticoid steroid 45 106
alprostadil Prestwick vasodilator, prostaglandin receptor agonist 45 82
maprotiline Prestwick antidepressant, noradrenaline uptake inhibitor 45 99
dobutamine Prestwick beta1-adrenergic agonist, bronchodilator 45 92
betamethasone Microsource US Drug glucocorticoid steroid 45 122
bromperidol Prestwick antipsychotic, dopamine antagonist 45 85
Non-toxic compounds that reduced the HMGB1-induced TNFa production by 2 standard deviation values are listed in order of potency, according to their inhibitory
potency for TNFa secretion. The source library of the compounds, their known biological activity and the respective viability values are shown. Viability was measured
by the MTT assay. (Abbreviations: MAP kinase: Mitogen-activated protein kinase, U0126:1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene, MEK: mitogen-
activated protein kinase kinase, STAT3: Signal transducer and activator of transcription 3, ST057244:1-[(2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]piperidin-2-one, Bay
11-7085: (2E)-3-[[4-(1,1-dimethylethyl)pheny?l]sulfonyl]-2-propenenitrile, Bay 11-7082:3- [(4- methylphenyl)sulfonyl]- (2E)- propenenitrile, ST009819: (2R,3R,13R,14R)-3-
(phenylcarbonyl)-17,19-dioxa-4-azapentacyclo[14.2.1.0,2,14.. 0,4,13..0,7,12.]nonadeca-5,7(12),8,10-tetraen-15-one, MNS: 3,4-methylenedioxy-b-nitrostyrene, IkB:
inhibitor of nuclear factor kB kinase, NF-kB: nuclear factor kB, HIV: human immunodeficiency virus, Src: sarcoma tyrosine kinase, Syk: Spleen tyrosine kinase).
doi:10.1371/journal.pone.0065994.t001
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Table 2. Compounds that enhance the HMGB1-induced TNFa production of RAW264.7 cells.




beta-escin Prestwick an increaser of calcium permeability, venous insufficiency drug 351 101
thapsigargin LOPAC sarco-endoplasmic reticulum Ca2+-ATPase inhibitor 336 13
niclosamide Microsource Killer anthelmintic, uncouples oxidative phosphorylation 335 67
wortmannin LOPAC phosphatidylinositol 3-kinase inhibitor 330 93
calcimycin LOPAC Ca2+ ionophore 327 1
gossypol LOPAC proapoptotic, binds calmodulin, PKC inhibitor, anti-HIV 321 88
niclosamide LOPAC anthelmintic, uncouples oxidative phosphorylation 302 39
tyrphostin A9 LOPAC PDGF tyrosine kinase receptor inhibitor 289 51
rottlerin LOPAC mitochondrial uncoupler 261 99
5-azacytidine Prestwick antineoplastic, pyrimidine antimetabolite 260 57
5-azacytidine Microsource US Drug antineoplastic, pyrimidine antimetabolite 257 84
vinblastine Microsource US Drug antineoplastic, spindle poison 256 86
imiquimod Prestwick immunomodulator, activator of Toll-Like Receptor 7 243 84
5-azacytidine Microsource Killer antineoplastic, pyrimidine antimetabolite 241 59
niclosamide Prestwick anthelmintic, uncouples oxidative phosphorylation 239 58
vincristine Microsource US Drug antineoplastic, microtubular agent 211 87
ivermectin ENZO FDA antiparasitic 206 86
gossypol Microsource Killer proapoptotic, binds calmodulin, PKC inhibitor, anti-HIV 204 112
rottlerin Natural Products mitochondrial uncoupler 196 77
pararosaniline Microsource US Drug anthelmintic, antischistosomal 195 89
podophyllotoxin Natural Products antineoplastic, microtubular agent 188 78
colchicine Microsource US Drug antineoplastic, microtubular agent 187 79
cantharidic acid LOPAC protein phosphatase 1 and 2A inhibitor 177 37
podophyllotoxin Microsource US Drug antineoplastic, microtubular agent 171 84
fluvastatin ENZO FDA statin, HMG-CoA reductase inhibitor 168 127
tyrphostin AG 879 LOPAC tyrosine kinase inhibitor with potent effects on TrkA 165 65
itavastatin NIH Clin. Collection statin, HMG-CoA reductase inhibitor 163 105
simvastatin Prestwick statin, HMG-CoA reductase inhibitor 162 106
fluvastatin Prestwick statin, HMG-CoA reductase inhibitor 162 111
8-azaguanine Prestwick antineoplastic, purine antimetabolite 159 74
methiazole Prestwick antiparasitic 159 77
N-oleoyldopamine LOPAC endogenous vanilloid, weak cannabinoid receptor ligand 158 24
oxaliplatin ENZO FDA antineoplastic DNA crosslinker 157 94
hexachlorophene Microsource Killer disinfectant, topical anti-infective, anti-bacterial agent 156 99
cerivastatin NIH Clin. Collection statin, HMG-CoA reductase inhibitor 156 100
colchicine Microsource Killer antineoplastic, microtubular agent 155 77
parbendazole Prestwick anthelmintic, microtubular agent 155 80
5-azacytidine LOPAC antineoplastic, pyrimidine antimetabolite 155 61
mevastatin LOPAC statin, HMG-CoA reductase inhibitor 153 110
tridihexethyl Prestwick anticholinergic antispasmodic 153 96
cerivastatin ENZO FDA statin, HMG-CoA reductase inhibitor 153 121
nordihydroguaiaretic acid LOPAC antioxidant from Larrea divaricata 153 113
norcantharidin LOPAC inhibitor of the serine/threonine protein phosphatase 2A 151 108
tannic acid Microsource Killer nonspecific enzyme/receptor blocker 150 99
Compounds augmenting the HMGB1-induced TNFa production by 2 standard deviation values are listed are listed in order of potency, according to their enhancing
effect on TNFaa secretion. The source library of the compounds, their known biological activity and the respective viability values are shown. Viability was measured by
the MTT assay. (Abbreviations: PKC: protein kinase C, HIV: human immunodeficiency virus, PDGF: platelet-derived growth factor, HMG-CoA: 3-hydroxy-3-methylglutaryl-
coenzyme A, TrkA: TRK1-transforming tyrosine kinase protein).
doi:10.1371/journal.pone.0065994.t002
Modulation of HMGB1-Mediated Inflammation
PLOS ONE | www.plosone.org 8 June 2013 | Volume 8 | Issue 6 | e65994
more pronounced at later time points (48 h, 72 h) (Fig. 2) and was
associated with a suppression of mitochondrial function (Fig. 3)
and caspase activation (Fig. 4). In addition to TNFa, HMGB1 also
upregulated multiple pro-inflammatory cytokine (IL1a, IL1b, IL6,
TNFb) and chemokine (Ccl2, MCP-1, Cxcl10) genes, as well as
the anti-inflammatory cytokine IL10 (Fig. 1C). The HMGB1-
mediated responses were also associated with an upregulation of
nuclear factor kB (NF-kB) (Fig. 1C). Moreover, HMGB1 induced
a down-regulation of TLR4 and MD2 and upregulation of TLR2,
TLR9 and TLR adaptor molecule 1 (Ticam1) (Fig. 1C). Thus, the
form of HMGB1 used for the screen exhibited the expected
cytokine like properties of C23-C45 disulfide C106 thiol HMGB1.
Identification of Inhibitors of HMGB1-induced TNFa
Production by Cell-based Screening
Cell-based screening of a focused library of over 5,000 clinical
drugs, natural products and pharmacologically active compounds
identified ,2% of the compounds, which suppressed TNFa
production, without adversely affecting cell viability (Table 1;
Fig. 5). Conversely, a limited number of compounds induced a
significant enhancement of HMGB1-mediated TNFa response
(Table 2). A full list of the primary screen data is deposited in
Table S2.
More than 50% of the hit compounds that inhibited TNFa
production were glucocorticoids (Fig. 5; Table 1). Beta-adrenergic
agonists represented the second-most common class. The activity
of the hit compounds was next confirmed at 3 and 10 mM. Since
glucocorticoids and beta agonists showed a clear class action, only
a subset of these compounds was retested. Apart from glucocor-
ticoids and beta agonists, the highest inhibitory activity was
detected for the NF-kB inhibitors Bay 11-7085 and parthenolide,
and the antioxidant piperlongumine. Increasing the concentration
of the compounds to 10 mM did not produce more pronounced
inhibitory responses, but approximately 15% of the hit compounds
became slightly cytotoxic at this concentration (Table 3).
Identification of Pharmacological Potentiators of
Glucocorticoids by Cell-based Screening
We hypothesized that synergistic drug combinations may be
more effective than single agents in controlling HMGB1-induced
inflammatory responses. To identify compounds that potentiate
the effect of glucocorticoids, a follow-up screen of the NIH Clinical
Collection compound library was conducted in the presence of
Figure 5. Screening for compounds that reduce the HMGB1-induced pro-inflammatory response. A: Timeline of the cell-based
screening: RAW 264.7 cells were pre-treated with test compounds and exposed to HMGB1 for 18 hours. TNFa production was measured from the
supernatant and the viability of the cells was measured by the MTT assay. B: Dot graph showing the individual TNFa/viability results of the tested
5,646 compounds. TNFa responses are shown as % values of the HMGB1-induced TNFa production. Values lower than MEAN-2SD are shown in red
(viability) and green (TNFa response) boxes to denote ‘‘toxic’’ and ‘‘Hit’’ compounds. C–D: Distribution of viability (C) and TNFa response (D) data
with superimposed Gaussian distribution curves fitted to the data points.
doi:10.1371/journal.pone.0065994.g005
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dexamethasone (3 mM). The screen identified beta2 agonists
(salbutamol, salmeterol), the phosphodiesterase (PDE) inhibitor
rolipram and as prostaglandin E1 as synergistic enhancers of the
glucocorticoid’s effect (Fig. 6, Table 4). In addition, the dopamine
receptor antagonist SCH 23390 (R)-(+)-7-chloro-8-hydroxy-3-
methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine HCl), the
structurally related benzodiazepine lorazepam, the antioxidant
ebselen and the d1 opioid receptor agonist SB 205607 decreased
TNFa production in the presence of the glucocorticoid. As
expected, the glucocorticoid receptor antagonist mifepristone
attenuated the effect of dexamethasone (Table 4). A few drugs
(e.g. cerivastatin, vindesine, vinorelbine) increased TNFa produc-
tion in the presence dexamethasone (Table 4); this effect was
related to the fact that, according to the results of the primary
screen, these compounds, on their own, increase HMGB1-induced
TNFa secretion (Table 1).
Glucocorticoid/beta-adrenergic Agonist Synergy:
Mechanism of Action
Using prednisolone (a prototypical glucocorticoid) and salbuta-
mol (a prototypical beta 2 adrenergic agonist), follow-up exper-
iments were designed to further characterize the pharmacological
properties and underlying mechanisms of the glucocorticoid/beta-
adrenergic synergy. Both prednisolone and salbutamol, on their
own, decreased the HMGB1-induced TNFa production in the low
nanomolar concentration range: they reached their maximum
effect at around 100–300 nM, exhibiting a 50% inhibition of
TNFa production (Fig. 7). Salbutamol (1 mM), in combination
Table 3. List of confirmed hit compounds.




TNFa response (% of HMGB1
stimulation)
3 mM 10 mM
Parthenolide NF-kB inhibitor Prestwick 2 92 2162 060*
Bay 11-7085 NF-kB inhibitor LOPAC 35 94 2561 261*
Ethylnorepinephrine beta adrenergic agonist US Drug 22 112 3160 2661
Halomethasone glucocorticoid NIH Clinical 39 106 3662 3461
Salbutamol beta adrenergic agonist Prestwick 38 102 3761 3766
Dexamethasone glucocorticoid Prestwick 23 100 3963 3062
Budesonide glucocorticoid LOPAC 41 115 4163 3861
Indinavir HIV protease inhibitor NIH Clinical 43 96 4263 4263
Ethacrynic acid diuretic US Drug 43 96 4460 361*
Fluticasone glucocorticoid NIH Clinical 40 93 4464 4361*
Hydrocortisone glucocorticoid LOPAC 39 110 4561 4563
Metaproterenol beta adrenergic agonist Prestwick 26 87 4863 5064
Fenoterol beta adrenergic agonist Prestwick 31 100 5161 5661
Ritodrine beta2 adrenergic agonist Prestwick 32 98 5164 4866
Terbutaline beta2 adrenergic agonist Prestwick 42 96 5162 5063
Isoflupredone glucocorticoid Prestwick 43 99 5265 5162
Clenbuterol beta adrenergic agonist Prestwick 32 98 5264 4465
MNS Src/Syk kinase inhibitor LOPAC 43 93 5462 961*
Ethacrynic acid diuretic Prestwick 45 98 5965 3962*
Levonordefrin adrenergic agonist Prestwick 45 116 6461 5668
PABA potassium salt vitamin Bx US Drug 43 118 6561 5961
Isoproterenol adrenergic agonist Prestwick 40 109 6762 5865
Prenylamine calcium channel blocker Prestwick 33 87 6964 5964
Tyloxapol surfactant US Drug 31 92 7860 5762
Isotretinoin retinoid US Drug 41 115 7962 6065
Piperlongumine antioxidant in peppers Nat. Prod. 0 94 8061 3963*
Lidocaine local anesthetic Prestwick 33 91 not tested
Hit compounds of the primary screen were retested in replicates at 3 and 10 mM against HMGB1 and LPS and compounds are shown that decreased the HMGB-induced
TNFa production by at least 40% in the hit confirmation experiments. (The majority of the glucocorticoids were not retested during the hit confirmation studies, since all
glucocorticoids showed similar activity, confirming their class action.) TNFa production and viability values are shown for the primary screen and the TNFa production is
shown for the hit confirmation experiments (Mean6SD). Compounds that reduced cell viability by at least 25% are labeled with an asterisk. (Abbreviations: Bay 11-7085:
(2E)-3-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-2-propenenitrile, MNS: 3,4-methylenedioxy-b-nitrostyrene, PABA potassium salt: para-aminobenzoic acid potassium salt,
NF-kB: nuclear factor kB, HIV: human immunodeficiency virus, Src: sarcoma tyrosine kinase, Syk: Spleen tyrosine kinase).
doi:10.1371/journal.pone.0065994.t003
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Table 4. Compounds of interest identified by screening of the NIH Library in the presence of 3 mM dexamethasone on HMGB1-
induced TNFa production.









Steroid action enhancers (potentiators)
salmeterol beta2 adrenergic agonist 50 102 21 111
rolipram phosphodiesterase inhibitor 60 86 23 109
prostaglandin E1 prostaglandin 55 97 23 109
salbutamol sulfate beta2 adrenergic agonist 51 91 25 110
lorazepam benzodiazepine 50 95 27 108
SB 205607 d1 opioid receptor agonist 53 102 29 110
R(+)-SCH-23390 HCl D1 dopamine receptor antagonist 73 96 30 110
ebselen anti-inflammatory antioxidant 85 103 34 117
Hit compounds in single-compound screen that do not enhance steroid action (non-potentiators)
fluticasone propionate glucocorticoid steroid 40 93 43 108
halometasone monohydrate glucocorticoid steroid 39 106 44 107
tadalafil PDE5 inhibitor 49 107 44 108
tropisetron HCl serotonin 5-HT3 antagonist 46 99 44 110
indinavir sulfate HIV protease inhibitor 43 96 48 105
beclomethasone glucocorticoid steroid 54 108 49 106
zaleplon GABA A a1 agonist hypnotic 52 101 50 109
desoximetasone glucocorticoid steroid 52 108 50 111
pergolide mesylate salt dopamine receptor agonist 60 99 54 110
loteprednol etabonate glucocorticoid steroid 59 104 62 108
Compounds that counteract dexamethasone (steroid inhibitors)
cerivastatin Na statin .150 100 83 126
rutin platelet aggregation inhibitor 102 97 69 112
ritonavir HIV protease inhibitor 112 98 73 113
vinorelbine bitartarate antineoplastic 112 78 78 106
vindesine sulfate mitotic inhibitor 120 69 96 84
mifepristone glucocorticoid receptor antagonist 101 101 92 115
Toxic compounds
dactinomycin antibiotics 1 1 0 2
triptolide NF-kB inhibitor 0 2 0 1
homoharringtonine 60-S ribosome inhibitor 0 1 1 1
idarubicin HCl anti-leukemic drug 6 2 9 2
epirubicin HCl anthracycline drug 12 2 18 15
doxorubicin HCl anthracycline drug 45 4 31 32
topotecan HCl topoisomerase inhibitor 94 49 45 94
indarubicin antineoplastic 100 72 54 94
diphenylcyclopropenone local immune response inducer 114 71 56 100
artesunate anti-malaria compound 121 74 75 78
vincristine sulfate mitotic inhibitor 130 72 90 80
Compounds of interest are shown with their respective TNFa response and viability values attained in the single compound and combined screens. Drugs that reduced
the TNFa response compared to the action of dexamethasone are classified as potentiators. Drugs that decreased the TNFa response by themselves, but showed
negligible increase in their activity in combination with dexamethasone are listed as non-potentiators. Compounds that resulted in higher TNFa secretion
(.MEAN+2SD) are listed as steroid inhibitors. Compounds that reduced the viability by more than 2 SD (,75% viability) are listed as toxic compounds.
doi:10.1371/journal.pone.0065994.t004
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with prednisolone, significantly reduced TNFa production already
at 10 nM (compared to salbutamol alone); at 100 nM predniso-
lone the combination reached its full potential (approximately
70% inhibition). Likewise, the combination of prednisolone (1 mM)
with 30 nM salbutamol significantly reduced the HMGB1-
induced TNFa response (compared to prednisolone alone) and
with 300 nM salbutamol the combination reached its full potential
(approximately 70% inhibition) (Fig. 7).
HMGB1-induced TNFaa secretion was associated with a rapid-
onset and marked increase in TNFa mRNA (Fig. 8). Prednisolone
and salbutamol each decreased the TNFa mRNA level by 50%;
combination of the two compounds synergistically inhibited the
transcription of TNFa mRNA (Fig. 8). We next tested whether the
early inhibition of TNFa production involves upstream signaling
events such as mitogen-activated protein kinase (MAPK) activa-
tion and IkB phosphorylation. HMGB1 induced an early and
sustained activation of the extracellular signal-regulated kinases 1/
2 (ERK1/2, p44 and p42) and p38 and of IkB phosphorylation
(Fig. 9). The combination of salbutamol and prednisolone resulted
in a partial, but statistically significant inhibition of ERK1
phosphorylation and IkB phosphorylation (Fig. 9). These data
indicate the regulation of HMGB1-mediated cellular signaling by
the glucocorticoid/beta-agonist combination has an upstream
regulatory component.
To further characterize the effect of the glucocorticoid/beta-
agonist combination on HMGB1-induced gene transcription, a
TLR signaling pathway array was next employed. The responses
could be characterized by four distinct expression patterns: a)
prednisolone, but not salbutamol inhibiting gene expression, b)
salbutamol, but not prednisolone inhibiting gene expression, c) the
two compounds synergistically blocking gene expression and d)
the two compounds synergistically enhancing gene expression
(Fig. 10). The genes which were mostly inhibited by steroids
included the interleukins (IL1a, Il1b, IL6, IL10) and Ptgs2 (COX-
2); the inhibition exerted by the beta-2 agonist was dominant in
case of the chemokines Ccl2 and Cxcl10 and TLR2 and TLR9;
synergistic inhibition by the glucocorticoid and the beta-agonist
was confirmed for TNFa, as well as demonstrated for lymphotoxin
(Lta) and the TLR adaptor Ticam1 (Fig. 10). Unexpectedly, in a
few instances, the steroid and the beta2 agonist led to a synergistic
enhancement, as seen with Csf3 (GCSF), CD14, CCAAT/enhancer-
binding protein beta (Cebpb), interleukin 1 receptor alpha (IL1R1)
and TLR8 (Fig. 10).
Given the fact that both glucocorticoids and beta-receptor
agonists represent endogenous hormones of the sympathetic-
adrenal-medullary axis, we have next evaluated whether cortisol
and/or adrenaline/noradrenaline, at concentrations that are
comparable to their endogenous plasma levels, affect HMGB1-
induced TNFa production. Cortisol, and, more markedly, the
combination of adrenaline and noradrenaline, suppressed the
HMGB1-induced TNFa response (Fig. 11).
Glucocorticoid/beta-adrenergic Agonist Synergy in vivo
The combination of prednisolone and salbutamol effectively
suppressed HMGB1-induced TNFa production in Balb/c male
mice in vivo, and this effect was more pronounced than the effect of
either agent alone (Fig. 12). In contrast, the glucocorticoid
receptor blocker mifepristone or the b-receptor antagonist
propranolol did not enhance HMGB1-induced TNFa production
(Fig. 12), suggesting that the response is not under significant
control by endogenous glucocorticoids acting on the mifepristone-
Figure 6. Combined screening to identify pharmacological potentiators of dexamethasone-mediated inhibition of the HMGB1-
induced pro-inflammatory response. RAW 264.7 cells were pre-treated with dexamethasone (3 mM) in combination with test compounds and
exposed to HMGB1 for 18 hours. TNFa production was measured from the supernatant and the viability of the cells was measured by the MTT assay.
A: TNFa responses measured in the combination screen are plotted versus the TNFa production values measured in the single compound screen.
TNFa production values higher than MEAN+2SD are shown in red (‘‘steroid inhibitors’’) and values lower than MEAN+2SD in green boxes
(‘‘potentiators of steroids) for the combination screen. Red dots denote the toxic compounds, green the steroid potentiators and purple those that
increase the TNFa production. Compounds that inhibited the HMGB-induced TNFa production in the single compound screen, but failed to
potentiate the action of steroids are shown in yellow. B: TNFa responses relative to the activity of dexamethasone are plotted versus the viability
values. Red and green boxes indicate the upper and lower 2 SD limits.
doi:10.1371/journal.pone.0065994.g006
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sensitive glucocorticoid receptor or by endogenous catecholamines
acting on the b-receptor.
Discussion
It is well established that HMGB1 plays a central role in sterile
inflammation [1–3]. This screen was undertaken to identify
inhibitors of HMGB1-induced, TLR4 dependent TNFa produc-
tion. The hit compounds emerging from the primary screen
included several signal transduction pathway modifiers, such as the
IkB phosphorylation inhibitor Bay 11-7085 and the Src/Syk
kinase inhibitor MNS. These findings are consistent with a role of
NF-kB and kinase activation in HMGB1-mediated cellular
signaling. Glucocorticoids and beta-receptor agonist activators of
intracellular cAMP (such as such as salbutamol, clenbuterol,
metaproterenol, ethylnorepinephrine and ritodrine) were two most
prominent drug classes emerging from the screen. Because of their
therapeutic potential, and because of the endogenous physiological
regulatory implications, these two classes of compounds were
subject of follow-up studies (see below). Additional classes of hit
compounds included the natural compounds, piperlongumine and
parthenolide (the latter compound is known pharmacological
actions as a NF-kB and MAP kinase inhibitor). The mechanism of
action and potential anti-inflammatory utility of miscellaneous
additional compounds that showed inhibitory effects - such as the
HIV protease inhibitor indinavir, the local anesthetic lidocaine,
the surfactant tyloxapol, the calcium antagonist prenylamine and
the diuretic ethacrynic acid - requires further characterization. It is
interesting to note that indinavir [18], tyloxapol [19] and lidocaine
[20] have previously been demonstrated to suppress TNFa
production in various experimental models in vitro, although the
underlying molecular pathways have not been fully characterized.
It is intriguing to speculate that these compounds may have
additional, hitherto unrecognized, secondary modes of pharma-
cological action (as well as potential therapeutic utility) due to
inhibition of HMGB1-mediated inflammatory responses.
We identified several different activators of intracellular cAMP
signaling as part of the screen for enhancers of the inhibitory effect
of glucocorticoids. The enhancers exerted their effects their effects
either through beta-adrenergic receptor agonism (such as salbu-
Figure 7. Prednisolone and salbutamol synergistically suppress HMGB1-induced TNFa secretion. RAW 264.7 cells were pretreated with
prednisolone and salbutamol at the indicated concentrations and exposed to HMGB1 (5 mg/ml) for 18 hours. TNFa secretion (A, B) and LDH release
(E, F) were measured in the supernatant. Cell viability (C, D) was measured by the MTT assay. (1p,0.05 HMGB1-treated group compared to vehicle
treated control, *p,0.05 compared to HMGB1 group, #p,0.05 compared to the respective first compound treatment).
doi:10.1371/journal.pone.0065994.g007
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tamol and salmeterol), through prolongation of the intracellular
half-life of cAMP (such as the phosphodiesterase inhibitor
rolipram) or by activating the cAMP-dependent protein kinase
(PKA) (such as prostaglandin E1). While neither the glucocorti-
coids nor the cAMP-stimulating agents, on their own, produced a
complete inhibition of HMGB1-mediated TNFa response, the
combination of these two agents yielded a robust inhibition, and
did so at low micromolar/nanomolar concentrations. Previous
studies have demonstrated synergistic interactions between steroids
and beta-agonists in various experimental systems in vitro and
suggested that cAMP and glucocorticoids act via distinct upstream
pathways, which activate transcription though separate hormone
response elements, the glucocorticoid receptor (GR) element
(GRE) and the cAMP-response element (CRE), respectively. The
site of the synergistic convergence was identified at the level of
inhibition of the promoter activation of various pro-inflammatory
genes [21–23]. Based on our findings, at least some of the
synergistic inhibition of HMGB1-induced signaling by the
glucocorticoid/beta-agonist combination occurs upstream from
NF-kB activation, upstream from GRE and CRE and upstream
from the promoter region of the inflammatory genes studied.
Our analysis of the gene expression profiles using a TLR
signaling pathway array demonstrated that the synergistic
inhibition of HMGB1-induced TNFa production by the gluco-
corticoid and the beta agonist does not represent a generalized
phenomenon. In the case of several mediators, neither the
glucocorticoid tested (e.g. Ccl2, Tlr2, Tlr9, Cd14, Cebpb, Csf3,
Tlr8), nor the beta agonist tested (e.g. Il-1a, IL1b, IL6, Csf3,
IL1r1) showed any inhibition. In some cases an enhancement was
seen (IL1ra, Ptgs2, IL-10). These findings clearly demonstrate that
HMGB1-mediated pro-inflammatory mediator production is
regulated by glucocorticoids and by cAMP in a fashion that is
specific to each gene product, and may be, at least in part, related
to individual differences in the steroid and cAMP-responsive
elements in individual promoters. Nevertheless, the combination
of the beta agonist and the glucocorticoid resulted in a partial
suppression for the majority of the genes studied, yielding a shift
towards an overall anti-inflammatory phenotype (without sup-
pressing the expression of the anti-inflammatory cytokine IL-10).
HMGB1 signals through numerous receptors, depending upon
the molecular conformation of the three cysteines [2,12–14,24–
26]. For example, extracellular HMGB1 is post-translationally
regulated via redox mechanisms, and the C23-C45 disulfide C106
Figure 8. Prednisolone and salbutamol inhibit the HMGB-induced TNFa production. RAW 264.7 cells were pretreated with prednisolone
(1 mM) and salbutamol (1 mM) and then exposed to HMGB1 (5 mg/ml) for various time up to 18 hours. A: TNFa secretion measured in the supernatant
is plotted versus exposure length. (MEAN6SD values are shown) B: TNFa mRNA expression, normalized to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), is shown as fold expression values of vehicle treated cells. (CTL: vehicle treated control, HMGB: cells exposed to HMGB1,
Pred: cells pretreated with prednisolone and exposed to HMGB1, Salb: cells pretreated with salbutamol and exposed to HMGB1, Pred+Salb: cells
pretreated with both prednisolone and salbutamol and exposed to HMGB1. 1p,0.05 HMGB1-treated group compared to vehicle treated control,
*p,0.05 compared to HMGB1 group, #p,0.05 compared to single compound treatment).
doi:10.1371/journal.pone.0065994.g008
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thiol conformation binds to and activates the TLR4/MD2
receptor complex in the absence of LPS [12–14]. Here we utilized
this recombinant conformation of HMGB1 (purified and charac-
terized as previously described), which primarily signals through
TLR4 to induce TNFa. Because RAGE and TLR2 are
dispensable for this effect, our studies would not be expected to
address signaling mediated through these receptors.
Hormones of the hypothalamic-pituitary-adrenal axis, the
sympathetic-adrenal-medullary axis, and the sympathetic and
parasympathetic arms of the autonomic nervous system have
powerful roles in the control of inflammation [27–31]. Adrenal-
ectomy or pharmacological blockade of endogenous glucocorticoid
receptors exacerbates [30], while beta-receptor activation sup-
presses systemic inflammatory responses [31]. Considering the fact
that the biologically active concentrations of glucocorticoids and
catecholamines in the current study are in the physiological range,
we have also explored whether the HMGB1-mediated inflamma-
tory responses are under the tonic control of these hormones.
While the combination of exogenous glucocorticoid and beta
agonist inhibited HMGB1-induced TNFa production (thereby
Figure 9. MAPK activation and IkB phosphorylation in response to HMGB1 are ameliorated in synergy by prednisolone and
salbutamol. A: RAW 264.7 cells were exposed to HMGB1 (5 mg/ml) for the indicated length and the phosphorylation of ERK1/2, p38 and IkB was
detected. B: RAW 264.7 cells pretreated with prednisolone (1 mM) and salbutamol (1 mM) were exposed to HMGB1 (5 mg/ml) for 30 min (ERK1/2, p38)
or 1 hour (IkB) and the activation was detected as phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204), phospho-p38 (Thr 180) or phospho-IkB-a (Ser 32/
36). C: Bar graph shows the phosphorylation signal normalized to the total amount of the respective protein. (CTL: vehicle treated control, HMGB:
cells exposed to HMGB1, Pred: cells pretreated with prednisolone and exposed to HMGB1, Salb: cells pretreated with salbutamol and exposed to
HMGB1, Pred+Salb: cells pretreated with both prednisolone and salbutamol and exposed to HMGB1. 1p,0.05 HMGB1-treated group compared to
vehicle treated control, *p,0.05 compared to HMGB1 group).
doi:10.1371/journal.pone.0065994.g009
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Figure 10. The interaction of prednisolone and salbutamol in the inhibition of HMGB-induced gene expression. RAW 264.7 cells
pretreated with prednisolone (1 mM) and salbutamol (1 mM) were exposed to HMGB1 (5 mg/ml) for 1.5 hours and the expression of TLR-associated genes was
analyzed with TLR signaling pathways array. Gene expression normalized to control genes (GAPDH, actin, B2m, Gusb, Hsp90ab1) is shown as fold expression
values of vehicle treated cells. (CTL: vehicle treated control, HMGB: cells exposed to HMGB1, Pred: cells pretreated with prednisolone and exposed to HMGB1,
Salb: cells pretreated with salbutamol and exposed to HMGB1, Pred+Salb: cells pretreated with both prednisolone and salbutamol and exposed to HMGB1.
1p,0.05 HMGB1-treated group compared to vehicle treated control, *p,0.05 compared to HMGB1 group, #p,0.05 compared to single compound treatment).
doi:10.1371/journal.pone.0065994.g010
Figure 11. Inhibition of the HMGB-induced inflammatory response by endogenous catecholamines and glucocorticoids at
physiological concentrations. RAW 264.7 cells were pretreated with cortisol (0.7 mM), noradrenaline (0.5 ng/ml), adrenaline (0.5 ng/ml),
dexamethasone (1 mM) and salbutamol (1 mM) and exposed to HMGB1 (5 mg/ml) for 18 hours. TNFa secretion was measured in the supernatant.
(1p,0.05 HMGB1-treated group compared to vehicle treated control, *p,0.05 compared to HMGB1 group, #p,0.05 cells treated with all
compounds in combination versus treated with a combination of two.).
doi:10.1371/journal.pone.0065994.g011
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extending the in vitro findings to an in vivo system), blockade of the
endogenous glucocorticoid receptors with mifepristone or inhibi-
tion of the beta receptors with propranolol failed to potentiate the
HMGB1-induced TNFa responses in vivo. Thus, circulating
HMGB1 does not result in a more severe inflammatory response
in subjects with impairment of their endogenous sympathetic-
adrenal-medullary homeostasis, at least in the current in vivo
experimental system.
In summary, the current study unveils several drug-like
modulators of HMGB1-mediated inflammatory responses and
offers pharmacological directions for the therapeutic suppression
of inflammatory responses in diseases driven by the HMGB1-
TLR4 axis. Glucocorticoids remain a mainstay of therapy for
rheumatoid arthritis, as well as many other inflammatory diseases.
In rheumatoid arthritis HMGB1 has been shown to play a
significant pathogenetic role [2,3]. We hypothesize that the mode
of the therapeutic action of glucocorticoids, in addition to
inhibiting HMGB1 release [11], also involves an inhibition of
HMGB1’s downstream signaling action. Furthermore, we con-
clude that the synergistic administration of a glucocorticoid and a
beta-receptor agonist or (another cAMP-elevating agent) is an
effective approach to suppress HMGB1-mediated inflammatory
responses in vitro and in vivo.
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Table S1 A full list of the genes investigated in the real-
time PCR array experiments.
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